David Holliday

With over 30 years of pharmaceutical and biologics experience, David has held progressively senior commercial roles in both private and public companies. He has successfully launched and commercialized a number of key >$1B biologics in the United Kingdom, United States, and other global markets, most recently, as VP Commercial Operations for Octapharma US. Prior to Octapharma US, he was Global Vice President of Marketing Operations and Hemophilia for Baxter (now Takeda) and also led their Bioscience business in the UK, following a 17-year career with Novartis. David holds a DMS from Kingston University in London.